AbCellera.
company in Vancouver, Canada
- Reports this week
- 1
- Active events
- 0
- Connections
- 37
What's happening
Earlier this month
One to three months ago
-
An FDA decision influenced AbCellera's stock climb, related to the company's work advancing immune treatments.Some support1 report
-
Vertex and AbCellera are collaborating to advance T cell therapies (TCEs) for autoimmune diseases.Some support2 reports1 development inside
-
AbCellera announced that its Phase II clinical trial data exceeded expectations for blockbuster potential on August 11, 2026.Some support1 report
-
AbCellera debuted on the Nasdaq stock exchange on August 4, 2026.Some support1 report
-
Competitors acquired companies involved in the same market, and Lynn Seely was appointed to the company's Board of Directors.Some support1 report
Gone quiet
No new reports in 90+ days-
Cantor Fitzgerald issued a coverage report on AbCellera, a company whose shares trade on Nasdaq.Some support2 reports
-
Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.Well supported4 reports
-
AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.Some support1 report
-
AbCellera and Bruker are involved in ongoing multi-patent infringement litigation.Speculative1 report
-
Leerink Partners affirmed an Outperform rating on AbCellera.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around AbCellera this week
News at the entities that move AbCellera most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves AbCellera
-
Bruker StructuralScott Bessent's call on August 23, 2025, amplified rate reduction sentiment, while Jerome Powell's comments spurred market uplift for Bruker.Moves AbCellera
-
Vertex OperationalVertex serves as Owner's Project Manager for the city.Moves AbCellera
-
Jazz Pharmaceuticals OperationalJazz Pharmaceuticals plans U.S. launch of Ziihera.Moves AbCellera
-
Sanofi OperationalSanofi and the Association of Science and Technology Centers announced a partnership focused on environmental education.Moves AbCellera
-
Benchmark TransactionalMarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.Moves AbCellera
Connections
The 12 strongest of 37, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bruker Structural
AbCellera is linked to Bruker via a subsidiary relationship, while also being involved in patent infringement litigation.
-
Jazz Pharmaceuticals Operational
The companies maintain an active partnership focused on joint collaboration and development of multispecific antibodies.
-
Vertex Operational
The companies are engaged in a strategic collaboration to develop Targeted Cell Engagements (TCEs) for autoimmune diseases.
-
FDA Structural
The FDA functions as the primary regulatory body whose decisions govern the market viability and operational status of AbCellera.
-
Sanofi Operational
The entities are competitors operating in the same market, driven by market acquisitions and consolidation.
-
Benchmark Transactional
Benchmark upgraded AbCellera's stock rating.
-
Rio de Janeiro Shared context
AbCellera is temporarily located in Rio de Janeiro to present data at a conference.
-
investing.com Mentioned together
investing.com reports on AbCellera's financial performance.
Show all 12 connections
-
British Columbia Shared context
AbCellera operates and is headquartered in British Columbia.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald has provided investment coverage and research reports on AbCellera.
-
Nasdaq Shared context
AbCellera is a company whose shares are listed and trade on the Nasdaq stock exchange.
-
Vancouver Shared context
AbCellera is headquartered and conducts business operations from its base in Vancouver, British Columbia.
History
Events by the month they beganAugust 2026
4 events- An FDA decision influenced AbCellera's stock climb, related to the company's work advancing immune treatments.
- Vertex and AbCellera are collaborating to advance T cell therapies (TCEs) for autoimmune diseases.
- AbCellera announced that its Phase II clinical trial data exceeded expectations for blockbuster potential on August 11, 2026.
- AbCellera debuted on the Nasdaq stock exchange on August 4, 2026.
July 2026
1 eventJune 2026
6 events- AbCellera, a company, is based in Vancouver, British Columbia.
- Cantor Fitzgerald issued a coverage report on AbCellera, a company whose shares trade on Nasdaq.
- Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.
- AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.
- AbCellera and Bruker are involved in ongoing multi-patent infringement litigation.
- Leerink Partners affirmed an Outperform rating on AbCellera.